Vaxart — Third Quarter 2026 Earnings Summary

Vaxart, Inc. reported third-quarter 2026 revenue of $10.6 million and a net loss of $17.7 million, with cash and investments totaling $65.5 million as of September 30, 2026. The company expects to release topline efficacy and safety data from its Phase 2b COVID-19 trial, which includes approximately 5,400 participants, by mid-year 2027. Recent developments include the receipt of a new European patent for its norovirus vaccine candidate and the publication of positive preclinical results for its H5N1 influenza vaccine candidate, VXA-H5-02. Additionally, the Board of Directors appointed Retired Vice Admiral Raquel C. Bono, M.D., to lead the newly established Stockholder Engagement Committee.